Diagnosis is Yes By which specialty Dermatologist Due to its rarity, diagnosis and treatment of required Clinical this condition is recommended to be limited Immunologist to Dermatologists or Clinical Immunologists. Diagnosis No By which specialty must be verified Exclusion Criteria Scleromyxedema (skin involvement only) unresponsive to steroids Qualifying and other immunosuppressant agents or where contra-indicated Criteria For patients with disease limited to the skin, Ig therapy will be authorised once patients have Moderate to severe scleromyxedema proven by skin biopsy demonstrated non-responsiveness to steroid and confirmed absence of thyroid disease therapy and treatment with at trial one immunosuppressant medication, unless AND contraindicated or unacceptable side effects or significant levels of toxicity have been Unresponsive to standard steroid therapy and at least one demonstrated. other immunosuppressant agent OR Immunosuppressant medication has resulted in unacceptable side effects or significant toxicity OR Corticosteroids and/or immunosuppressant agents are contraindicated
Diagnosis is required Yes By which specialty Dermatologist Clinical Immunologist Due to its rarity, diagnosis and treatment of this condition is recommended to be limited to Dermatologists or Clinical Immunologists. Diagnosis must be verified No By which specialty Exclusion Criteria Qualifying Criteria Scleromyxedema (skin involvement only) unresponsive to steroids and other immunosuppressant agents or where contra-indicated Moderate to severe scleromyxedema proven by skin biopsy and confirmed absence of thyroid disease AND Unresponsive to standard steroid therapy and at least one other immunosuppressant agent OR Immunosuppressant medication has resulted in unacceptable side effects or significant toxicity OR Corticosteroids and/or immunosuppressant agents are contraindicated For patients with disease limited to the skin, Ig therapy will be authorised once patients have demonstrated non-responsiveness to steroid therapy and treatment with at one immunosuppressant medication, unless contraindicated or unacceptable side effects or significant levels of toxicity have been demonstrated. trial
Scleromyxedema2017.docx